Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 14/20 | 0.75 |
| ▸ | KDR | P35968 | 6/20 | 0.75 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.75 |
| ▸ | BRAF | P15056 | 5/20 | 0.75 |
| ▸ | RET | P07949 | 4/20 | 0.75 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.75 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.75 |
| ▸ | ABL1 | P00519 | 3/20 | 0.75 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.75 |
| ▸ | MAP3K20 | Q9NYL2 | 3/20 | 0.75 |
| ▸ | PLK4 | O00444 | 2/20 | 0.75 |
| ▸ | AURKA | O14965 | 2/20 | 0.75 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.75 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.75 |
| ▸ | LCK | P06239 | 2/20 | 0.75 |
| ▸ | FYN | P06241 | 2/20 | 0.75 |
| ▸ | LYN | P07948 | 2/20 | 0.75 |
| ▸ | SRC | P12931 | 2/20 | 0.75 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.75 |
| ▸ | AXL | P30530 | 2/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14481178 | 0.93 | RAF1 (0.71) | RAF1KDRMAPK14BRAFRET | |
| SCHEMBL14550467 | 0.93 | RAF1 (0.66) | RAF1KDRMAPK14BRAFRET | |
| SCHEMBL10105571 | 0.92 | RAF1 (0.66) | RAF1KDRMAPK14BRAFRET | |
| SCHEMBL15218623 | 0.92 | KDR (0.64) | RAF1KDRMAPK14BRAFRET | |
| SCHEMBL15971160 | 0.90 | KDR (0.81) | RAF1KDRMAPK14BRAFRET | |
| SCHEMBL13946016 | 0.90 | RAF1 (0.61) | RAF1KDRMAPK14BRAFRET | |
| SCHEMBL18016178 | 0.90 | RAF1 (0.61) | RAF1KDRMAPK14BRAFRET | |
| SCHEMBL22594900 | 0.89 | RAF1 (0.75) | RAF1KDRMAPK14BRAFRET | |
| SCHEMBL10105553 | 0.89 | RAF1 (0.79) | RAF1KDRMAPK14BRAFRET | |
| SCHEMBL171188 | 0.89 | RAF1 (0.61) | RAF1KDRMAPK14BRAFRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330061-A1 | ANTIMICROBIAL COMPOSITIONS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | NATIONAL TAIWAN UNIVERSITY (TW) | 2023-10-19 | — | — | US | disclosed |
| US-9889123-B2 | Polymorphs of deuterated omega-diphenylurea or salts thereof | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. (CN) | 2018-02-13 | — | — | US | disclosed |
| US-20170128427-A1 | POLYMORPHS OF DEUTERATED OMEGA-DIPHENYLUREA OR SALTS THEREOF | SUZHOU ZELGEN BIOPHARMACEUTICALS CO., LTD. (CN) | 2017-05-11 | — | — | US | disclosed |
| US-9573900-B2 | Polymorphs of deuterated omega-diphenylurea or salts thereof | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. (CN) | 2017-02-21 | — | — | US | disclosed |
| US-9358231-B2 | Type II RAF kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20160058751-A1 | COMPOSITION AND METHOD FOR TREATING CANCER | CELLWORKS GROUP, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160046636-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-18 | — | — | US | disclosed |
| US-9260417-B2 | Therapeutic methods and compositions involving allosteric kinase inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20160022642-A1 | Compounds Useful for Promoting Protein Degradation and Methods Using Same | YALE UNIVERSITY | 2016-01-28 | — | — | US | disclosed |
| US-9180127-B2 | Type II Raf kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20130040949-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-8216571-B2 | Fully human anti-VEGF antibodies and methods of using | SCHERING CORPORATION (US) | 2012-07-10 | — | — | US | disclosed |
| US-20110097340-A1 | FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING | XOMA TECHNOLOGY LTD. | 2011-04-28 | — | — | US | disclosed |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-7645747-B2 | Improved pharmacokinetic properties, oral bioavailability; side effect reduction | GILEAD SCIENCES, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090181930-A1 | KINASE INHIBITORY PHOSPHONATE ANALOGS | CANNIZZARO CARINA | 2009-07-16 | — | — | US | disclosed |
| US-20090053236-A1 | USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7417055-B2 | Kinase inhibitory phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-20070281907-A1 | Kinase Inhibitor Phosphonate Conjugates | GILEAD SCIENCES, INC. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110097340-A1 | FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING | VEGFA, KDR, FLT4 | RAF1 1284/4885KDR 2/4885MAPK14 1765/4885 |
| US-20160058751-A1 | COMPOSITION AND METHOD FOR TREATING CANCER | KRAS, NRAS, TP53 | RAF1 11/4885KDR 953/4885MAPK14 1253/4885 |
| US-20230330061-A1 | ANTIMICROBIAL COMPOSITIONS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | FASN, NAAA, FPR3 | RAF1 1167/4885KDR 4172/4885MAPK14 3696/4885 |
| US-20160022642-A1 | Compounds Useful for Promoting Protein Degradation and Methods Using Same | AR, SHBG, PSMG3 | RAF1 3474/4885KDR 3615/4885MAPK14 4015/4885 |
| US-20090181930-A1 | KINASE INHIBITORY PHOSPHONATE ANALOGS | PIK3CA, PNKP, PIK3CB | RAF1 320/4885KDR 860/4885MAPK14 377/4885 |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | PIK3CA, PHOSPHO1, PTEN | RAF1 1304/4885KDR 1628/4885MAPK14 1559/4885 |
| US-20160046636-A1 | TYPE II RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | RAF1 2/4885KDR 657/4885MAPK14 182/4885 |
| US-20130040949-A1 | TYPE II RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | RAF1 2/4885KDR 657/4885MAPK14 182/4885 |
| US-20090053236-A1 | USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR | KIT, FLT4, KDR | RAF1 285/4885KDR 3/4885MAPK14 576/4885 |
| US-20070281907-A1 | Kinase Inhibitor Phosphonate Conjugates | PIK3CA, PNKP, PLK1 | RAF1 409/4885KDR 593/4885MAPK14 508/4885 |
| US-20170128427-A1 | POLYMORPHS OF DEUTERATED OMEGA-DIPHENYLUREA OR SALTS THEREOF | PLD2, PLD1, PTGER1 | RAF1 7/4885KDR 1969/4885MAPK14 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.